Key Highlights
- Amazon One Medical introduced a comprehensive GLP-1 weight management service integrating virtual consultations, medication prescriptions, and pharmacy delivery.
- Program pricing for insured members begins at $25 monthly; cash-pay injectable medications such as Wegovy and Zepbound start at $299 monthly.
- The e-commerce giant targets same-day medication delivery expansion to 4,500 municipalities by late 2026.
- Hims & Hers (HIMS) experienced a pre-market decline of up to 6% after Amazon’s announcement.
- Analysts at Bank of America forecast a potential 31% impact on HIMS’s GLP-1 business due to heightened competition.
Amazon has entered the obesity medication market with substantial infrastructure. The tech and retail powerhouse announced Tuesday its GLP-1 management initiative via Amazon One Medical, the company’s primary healthcare division, creating an integrated obesity treatment solution with pharmacy services and telehealth consultations.
The initiative provides access to brand-name treatments from pharmaceutical leaders, including Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. Members with insurance coverage can obtain oral GLP-1 medications for as little as $25 monthly. Self-pay patients face costs starting at $149 monthly for oral formulations, while injectable treatments like Wegovy and Zepbound carry a starting price of $299 monthly.
The pricing structure aligns with existing market rates. However, Amazon’s competitive advantage centers on accessibility — rapid same-day fulfillment powered by its established distribution infrastructure and streamlined patient experience from initial assessment through ongoing prescription management.
Tanvi Patel, VP and GM of Amazon Pharmacy, emphasized the program’s focus on helping patients “stay on those medications because they are delivered reliably directly to patients.”
The service has launched nationwide and frames weight management as an ongoing chronic condition requiring continuous care rather than short-term intervention. The program encompasses preliminary screening, organized medical consultations, scheduled follow-up appointments, and clinically validated treatment approaches.
Patients can request prescription renewals on-demand, with messaging consultations priced at $29 and video consultations at $49. Amazon has set an ambitious target to bring same-day delivery capabilities to 4,500 cities before 2027 arrives.
Competitive Pressure on HIMS
The market responded swiftly to Amazon’s entry. Hims & Hers Health experienced sharp selling pressure, with shares declining as much as 6% during pre-market hours before recovering somewhat during regular trading. Investor sentiment reflects mounting anxiety about Amazon’s encroachment into the affordable GLP-1 segment where HIMS has established presence.
The development arrives at a challenging moment for HIMS. The telehealth company has recently pivoted its strategy toward branded obesity medications — the premium segment of the market — concurrent with Amazon’s rollout of a competing comprehensive service. Analysts at Bank of America have projected this competitive dynamic could reduce HIMS’s GLP-1 revenue stream by 31%.
Additional companies operating in the obesity pharmaceutical sector experienced downward pressure Tuesday, including Viking Therapeutics (VKTX), Amgen (AMGN), and Septerna (SEPN).
Building on Amazon’s GLP-1 Strategy
Amazon’s Tuesday announcement represents the latest chapter in an evolving obesity treatment strategy. Earlier this year in January, the company introduced same-day fulfillment for Novo Nordisk’s Wegovy obesity medication. By April, Amazon had extended same-day delivery to Eli Lilly’s recently approved weight-loss pill, Foundayo, through its digital pharmacy platform.
Tuesday’s program unifies these separate initiatives into a cohesive ecosystem — combining primary medical care, pharmaceutical services, and telehealth appointments within a single integrated platform.
Analyst sentiment toward AMZN remains overwhelmingly positive, with a Strong Buy consensus based on ratings from 45 Wall Street analysts — 42 recommend buying while 3 suggest holding. The consensus price target of $286.74 indicates potential upside of approximately 13% from current trading levels.
AMZN stock advanced roughly 1% in trading following the program announcement.
